RSS Feed Print
Doctors seek trial for Montelukast (Singulair) for Covid-19
Larrytherunner
Posted: Sunday, May 3, 2020 12:34 PM
Joined: 2/26/2016
Posts: 225


In 2017, I ran across an article about using montelukast to prevent and treat viral pneumonia resulting from the flu and other respiratory viral infections. After reading the article, I sent an email to Dr Braciale at the University of Virginia and he responded that the university had put in a request for a federal government sponsored clinical trial for this drug for the treatment of viral pneumonia. Montelukast is now a generic drug, so no drug company is interested in paying for a clinical trial. Before the start of the covid-19 pandemic, there was also not much interest coming from the federal government.

 

When patients are infected with viral respiratory diseases like the flu, MERS, SARS, and the covid-19, they can develop viral pneumonia. When this happens, these diseases become much more deadly.

 

According to the attached article, doctors at Coney Island Hospital in NY are treating Covid-19 patients with montelukast with good results. This drug seems to slow down the overactivation of the immune system which occurs in viral pneumonia. According to the article, a montelukast covid-19 trial is coming soon. This will be an emergency trial done in a short time period.

I would like to point out that this not a drug company seeking a trial. These are doctors that are treating patients seeking a trial.

 

"An Allergy Medicine Singulair (Montelukast) is Showing Promising Results on COVID-19 patients | Ask Health News" https://askhealthnews.com/6828/an-allergy-medicine-singulair-montelukast-is-showing-promising-results-on-covid-19-patients/amp/

 

https://news.virginia.edu/content/asthma-drugs-could-prevent-deadly-form-pneumonia-research-suggests